Lexeo Therapeutics, (NASDAQ: LXEO) — Perfil da empresa, notícias e dados financeiros
Lexeo Therapeutics is a biotechnology firm developing gene therapies for cardiovascular, neurodegenerative and rare diseases.
Lexeo Therapeutics,
Lexeo Therapeutics (NASDAQ:LXEO) is a biotechnology firm focused on developing genetic medicines for life-altering disorders. Their portfolio spans a range of projects aimed at tackling cardiovascular, neurodegenerative, and rare diseases. By leveraging cutting-edge gene therapy technologies, Lexeo Therapeutics strives to bring innovative treatments from the lab to patients in need. Their objectives center on advancing their clinical pipeline, prioritizing safety and efficacy, and ultimately improving patient outcomes. Their commitment to research and development is driven by a deep understanding of genetic medicine's potential to offer transformative therapies.
Resumo
Operações
Produtos e/ou serviços de Lexeo Therapeutics,
- Gene therapy for Friedreich’s Ataxia, focusing on correcting the genetic defect causing this neurodegenerative disease.
- A gene therapy approach targeting APOE4-related Alzheimer’s disease, aiming to address genetic risk factors.
- Development of therapies for genetic forms of cardiomyopathy, aiming to address heart muscle disorders.
- Innovative treatments for Parkinson’s disease, focusing on genetic contributors to improve disease management.
- Gene editing technologies targeting rare genetic disorders, offering potential cures or substantial improvements.
- Advanced drug delivery systems enhancing the efficacy and safety of gene therapies.
equipe executiva do Lexeo Therapeutics,
- R. Nolan TownsendCEO & Director
- Louis TamayoCFO & Principal Accounting Officer
- Ronald G. CrystalCo-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
- Jose Manuel OteroChief Operating Officer
- Narinder P. BhallaChief Medical Officer
- Keith WonnacottSenior Vice President of Regulatory Affairs
- Ashley KaplowitzHead of Capital Markets
- Ryan McHenryVP & Corporate Controller
Últimas notícias sobre a Lexeo Therapeutics,
Principais indicadores financeiros
Resultados divulgados pela Lexeo Therapeutics, , em USD.
- Cap. de mercado
- 256,9 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -1.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -109,3 mi | -100 mi | |
| 0 | -105,8 mi | -98,3 mi | |
| 0 | -68,5 mi | -66,4 mi | |
| 654 mil | -60,5 mi | -59,3 mi |